statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Kite, a Gilead Company (Nasdaq: GILD), today announced 12 abstracts from its industry-leading Chimeric Antigen Receptor (CAR) T-cell therapy portfolio at the upcoming 2024 European Hematology...

Kite Data at EHA 2024 Demonstrate Positive Patient Outcomes and Advances in Delivery of CAR T-cell Therapy

Decoding Gilead Sciences's Options Activity: What's the Big Picture?

Arcellx, Inc. (NASDAQ: ACLX) and Kite, a Gilead Company (NASDAQ: GILD), today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma...

Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX) today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma...

Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will present 18 abstracts during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. These data showcase the ongoing...

Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024

Gilead Sciences Unusual Options Activity For May 06

How Is The Market Feeling About Gilead Sciences?

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: BofA Securities Health Care Conference on Tuesday, May 14 at 11:20am...

Gilead Sciences to Present at Upcoming Investor Conferences

Gilead Sciences Unusual Options Activity

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) approved an updated label with additional data reinforcing the safety and efficacy profile of Biktarvy...

FDA Approves Biktarvy Label Update With Data for Pregnant Adults With HIV

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Gilead Sciences, Inc.

Watchers	76,485
52-Wk Low	$64.33
52-Wk High	$87.87

Volume	2.43M
52-Wk High	$87.87
52-Wk Low	$64.33

GILD Gilead Sciences, Inc.

About

Feed

News

Sentiment

Earnings

Fundamentals

Sentiment

Message Volume

Community